Genotype-guided switch from ravulizumab to satralizumab in aquaporin-4–IgG–positive neuromyelitis optica spectrum disorder: a case of C5 polymorphism-associated ravulizumab resistance
Ethical approval and informed consent
Written informed consent was obtained from the patient for the publication of this case report.
Conflict of interest
The authors declare that they have no conflicts of interest.
Comments (0)